Drug
Rondecabtagene Autoleucel
Rondecabtagene Autoleucel: highest development phase Phase 3, developed by Lyell Immunopharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Lyell Immunopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| rondecabtagene autoleucel NCT07188558 | Phase 3 | Large B-cell Lymphoma |
| Rondecabtagene autoleucel (ronde-cel) NCT05826535 | Phase 1/2 | Relapsed Non-Hodgkin Lymphoma |
Latest
No recent events.
Follow Rondecabtagene Autoleucel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.